Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01012830|
Recruitment Status : Unknown
Verified November 2009 by VA Nebraska Western Iowa Health Care System.
Recruitment status was: Not yet recruiting
First Posted : November 13, 2009
Last Update Posted : November 13, 2009
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia Dementia||Drug: Huperzine A||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Huperzine-A for Cognitive Dysfunction and Functional Status in Schizophrenia|
|Study Start Date :||December 2009|
|Estimated Primary Completion Date :||December 2010|
|Estimated Study Completion Date :||April 2011|
Experimental: Huperzine A
200 micrograms (mcg) of HuperzineA taken twice daily.
Drug: Huperzine A
Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
- MATRICS Consensus Cognitive Battery [ Time Frame: First visit, 4 weeks, 8 weeks ]
- University of California Performance Skills Assessment-Brief (UPSA-B) [ Time Frame: First visit, 8 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01012830
|Contact: Daniel A Ramirez, BS||800-451-5796 ext 4036||Daniel.Ramirez@va.gov|
|United States, Nebraska|
|Veterans Affairs Nebraska Western Iowa Health Care System|
|Omaha, Nebraska, United States, 68105|
|Contact: Daniel A Ramirez, BS 800-451-5796 ext 4036 Daniel.Ramirez@va.gov|
|Principal Investigator: Prasad R Padala, MD, MS|
|Principal Investigator:||Prasad R Padala, MD, MS||VA Office of Research and Development|